

**FAX**

Date: NOV. 1, 2002

From: Lisa Hazzard

Zip:

Fax:

Phone:

Total Pages (including cover): 2  
If you do not receive all pages, please contact at**E  
&  
A****EDWARDS & ANGELL, LLP**

101 FEDERAL STREET

BOSTON, MA 02110

TELEPHONE: (617) 439-4444

FAX: (617) 439-4170 OR (617) 439-7748

To: Examiner Srivastava

FAX NUMBER: 703-746-5210

DIRECT NUMBER:

To:

FAX NUMBER:

DIRECT NUMBER:

To:

FAX NUMBER:

DIRECT NUMBER:

Message:

USSN 09/669,051

Proposed claims for discussion during  
Nov. 5, 2002 Interviews (10:00am)**Confidentiality Note**

This facsimile contains privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this facsimile is not the intended recipient or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination or copying of this facsimile is strictly prohibited. If you have received this facsimile in error, please notify us immediately by telephone (call collect) and return the original facsimile to us at the above address via the U.S. Postal Service. We will reimburse you for postage. Thank you.

BOSTON FT. LAUDERDALE HARTFORD LONDON NEW YORK PROVIDENCE SHORT HILLS, NJ WEST PALM BEACH

Received from &lt; 617 439 4170 &gt; at 11/1/02 1:00:44 PM [Eastern Standard Time]

USSN: 09/669,051

## PROPOSED CLAIMS FOR DISCUSSION (NOVEMBER 5, 2002 INTERVIEW)

1. A method for treating an obstructed biological conduit, comprising administering to the wall of the biological conduit an agent that can degrade the extracellular matrix of obstructing tissue, wherein administration of the agent results in proteolysis of elastin and/or elastin microfibers in the wall of the biological conduit.
2. The method of claim 1, wherein the biological conduit is an artery or vein that is obstructed or susceptible to obstruction.
3. The method of claim 1, wherein administration of the agent comprises inserting a delivery apparatus into the wall of the biological conduit.
4. The method of claim 3, wherein the method further comprises the step of localizing the delivery apparatus in close proximity to the obstructed segment of the biological conduit to be treated.
5. The method of claim 1, wherein the proteolysis of elastin and/or elastin microfibers in the wall of the biological conduit leads to enlargement of the diameter of the treated biological conduit.
6. The method of claim 1 wherein the lumen of the biological conduit is pressurized while elastin and/or elastin microfibers in the wall are undergoing proteolysis.
7. The method of claim 1 wherein the agent stimulates the release of endogenous enzymes that hydrolyzes elastin and/or elastin microfibers.